PMID- 18001407
OWN - NLM
STAT- MEDLINE
DCOM- 20080211
LR  - 20220316
IS  - 1083-4389 (Print)
IS  - 1083-4389 (Linking)
VI  - 12
IP  - 6
DP  - 2007 Dec
TI  - Double-dose, new-generation proton pump inhibitors do not improve Helicobacter 
      pylori eradication rate.
PG  - 638-42
AB  - BACKGROUND: Up to present, omeprazole plus two antibiotics are used for 
      Helicobacter pylori eradication therapy . Few studies have compared double-dose 
      new-generation, proton pump inhibitors (PPI) with omeprazole. Therefore, we 
      conducted a randomized, prospective study to evaluate differences in H. pylori 
      eradication rates by PPI type. MATERIAL AND METHODS: Between January 2006 and 
      December 2006, 576 consecutive patients with proven H. pylori infection were 
      enrolled prospectively. Four different PPIs [omeprazole 20 mg b.i.d. (old 
      generation), or pantoprazole 40 mg b.i.d., rabeprazole 20 mg b.i.d., or 
      esomeprazole 40 mg b.i.d. (new generation)] were added to clarithromycin (500 mg 
      b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week. RESULTS: By intention-to-treat 
      analysis, no difference was found between the eradication rates of these four 
      PPIs: 64.9% (omeprazole, n = 148), 69.3% (pantoprazole, n = 140), 69.3% 
      (rabeprazole, n = 140), and 72.9% (esomoprazole, n = 148). When eradication rates 
      were analyzed according to whether patients had an ulcer or not on a per-protocol 
      basis, no difference was found between the eradication rates of the four PPIs. 
      However, side-effects were more common in the esomeprazole-based triple therapy 
      group than in the other groups (p < .05). CONCLUSIONS: No convincing evidence was 
      obtained that double-dose new-generation PPIs have better H. pylori eradication 
      rates and tolerability than omeprazole.
FAU - Choi, Hyo Sun
AU  - Choi HS
AD  - Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan 
      University School of Medicine, Jongro-gu, Seoul, South Korea.
FAU - Park, Dong Il
AU  - Park DI
FAU - Hwang, Sang Jun
AU  - Hwang SJ
FAU - Park, Jung Sik
AU  - Park JS
FAU - Kim, Hong Joo
AU  - Kim HJ
FAU - Cho, Yong Kyun
AU  - Cho YK
FAU - Sohn, Chong Il
AU  - Sohn CI
FAU - Jeon, Woo Kyu
AU  - Jeon WK
FAU - Kim, Byung Ik
AU  - Kim BI
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - D8TST4O562 (Pantoprazole)
RN  - H1250JIK0A (Clarithromycin)
RN  - KG60484QX9 (Omeprazole)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/therapeutic use
MH  - Adult
MH  - Amoxicillin/administration & dosage/therapeutic use
MH  - Anti-Ulcer Agents/administration & dosage/*therapeutic use
MH  - Clarithromycin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Esomeprazole
MH  - Female
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - Helicobacter pylori/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage/therapeutic use
MH  - Pantoprazole
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
MH  - Rabeprazole
EDAT- 2007/11/16 09:00
MHDA- 2008/02/12 09:00
CRDT- 2007/11/16 09:00
PHST- 2007/11/16 09:00 [pubmed]
PHST- 2008/02/12 09:00 [medline]
PHST- 2007/11/16 09:00 [entrez]
AID - HEL556 [pii]
AID - 10.1111/j.1523-5378.2007.00556.x [doi]
PST - ppublish
SO  - Helicobacter. 2007 Dec;12(6):638-42. doi: 10.1111/j.1523-5378.2007.00556.x.